Exploring SARS-CoV-2 and
ACE2
CD147
COVID-19
malaria
novel coronavirus
red blood cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
12
2022
accepted:
27
02
2023
medline:
31
3
2023
entrez:
30
3
2023
pubmed:
31
3
2023
Statut:
epublish
Résumé
The co-occurrence and the similarities between malaria and COVID-19 diseases raise the question of whether SARS-CoV-2 is capable of infecting red blood cells and, if so, whether these cells represent a competent niche for the virus. In this study, we first tested whether CD147 functions as an alternative receptor of SARS-CoV-2 to infect host cells. Our results show that transient expression of ACE2 but not CD147 in HEK293T allows SARS-CoV-2 pseudoviruses entry and infection. Secondly, using a SARS-CoV-2 wild type virus isolate we tested whether the new coronavirus could bind and enter erythrocytes. Here, we report that 10,94% of red blood cells had SARS-CoV-2 bound to the membrane or inside the cell. Finally, we hypothesized that the presence of the malaria parasite,
Identifiants
pubmed: 36993979
doi: 10.3389/fimmu.2023.1120298
pmc: PMC10041564
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1120298Informations de copyright
Copyright © 2023 López-Farfán, Irigoyen and Gómez-Díaz.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Microbe. 2022 Jan;3(1):e62-e71
pubmed: 34723228
PLoS Negl Trop Dis. 2021 Oct 1;15(10):e0009766
pubmed: 34597315
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Stem Cell Reports. 2021 May 11;16(5):1165-1181
pubmed: 33979601
Nature. 2011 Nov 09;480(7378):534-7
pubmed: 22080952
Int J Mol Sci. 2022 Feb 25;23(5):
pubmed: 35269703
Stem Cell Reports. 2021 Mar 9;16(3):428-436
pubmed: 33581053
BMC Infect Dis. 2022 Jan 22;22(1):78
pubmed: 35065613
mSphere. 2021 Aug 25;6(4):e0064721
pubmed: 34378982
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Wellcome Open Res. 2020 Jul 29;5:181
pubmed: 33283055
Blood. 2020 Oct 15;136(16):1888-1891
pubmed: 32871595
New Microbes New Infect. 2020 Nov;38:100817
pubmed: 33230417
Biologicals. 2020 Nov;68:122-124
pubmed: 32891497
Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Sci Rep. 2021 Jan 11;11(1):413
pubmed: 33432067
Int J Mol Sci. 2014 Apr 15;15(4):6356-77
pubmed: 24739808
Virology. 1995 Feb 1;206(2):935-44
pubmed: 7531918
Biochem Biophys Res Commun. 2020 May 21;526(1):135-140
pubmed: 32199615
PLoS Pathog. 2021 Jun 17;17(6):e1009644
pubmed: 34138976
Am J Physiol Lung Cell Mol Physiol. 2021 Aug 1;321(2):L485-L489
pubmed: 34231390
Front Microbiol. 2019 Nov 08;10:2652
pubmed: 31787966
Front Public Health. 2022 Dec 12;10:1048404
pubmed: 36579069
Signal Transduct Target Ther. 2020 Dec 4;5(1):283
pubmed: 33277466
Oncotarget. 2017 Apr 11;8(15):25806-25813
pubmed: 28445958
Curr Opin Hematol. 2007 May;14(3):203-9
pubmed: 17414208
Public Health. 2021 May;194:33-35
pubmed: 33852995
OMICS. 2021 Aug;25(8):475-483
pubmed: 34280038